Prevalence of red blood cell alloimmunization in patients with sickle cell anemia

Main Article Content

Alexandre Gomes Vizzoni
Heladya Maria Matos Moreira

Abstract

Although packed red blood cells transfusions are important for treating patients with sickle cell anemia, this intervention may lead to immunological disturbs, such as alloimmunization by erythrocyte antigens. Approximately 50% of patients with sickle cell anemia receive blood transfusions during their life span, and about 5 to 10% of them require a chronic transfusion scheme. The red blood cell alloimmunization is a serious but common transfusion reaction. This condition could lead to delayed hemolytic transfusion reactions, contributing to increase comorbidities of the disease. Important measures to prevent these complications in patients are the use of previously phenotyped red blood cells, in addition to the phenotyping of red blood cells from the acceptor patient, determining the correct phenotypic profile and enabling the choice of red blood cells with corresponding antigens to the patient to be transfused. Extensive prophylactic red blood cell genotyping to select donors for patients receiving repeated transfusions over a long period of time is a compelling application of DNA-based blood typing. This is particularly relevant for patients with sickle cell disease where the rate of alloimmunization is high.

Downloads

Download data is not yet available.

Article Details

How to Cite
Vizzoni, A. G., & Moreira, H. M. M. (2017). Prevalence of red blood cell alloimmunization in patients with sickle cell anemia. ABCS Health Sciences, 42(1). https://doi.org/10.7322/abcshs.v42i1.950
Section
Review Articles

References

1. Bandeira FMGC, Santos MNN, Bezerra MAM, Gomes YM, Araújo AS, Braga MC, et al. Triagem familiar para o gene HBB*S e detecção de novos casos de traço falciforme em Pernambuco. Rev Saúde Pública. 2008;42(2):234-41. http://dx.doi.org/10.1590/S0034-89102008005000002

2. Silva RA, Souza AVV, Mendes SO, Luz PRG, Medeiros MO. Estudo genético-populacional da doença falciforme a partir de doadores de sangue em primavera do Leste-MT. Biodiversidade. 2012;11(1):108-14.

3. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Manual de diagnóstico e tratamento de doenças falciformes. Brasília: ANVISA; 2001. 142p.

4. Stypulkowski JB, Manfredini V. Alterações hemostáticas em pacientes com doença falciforme. Rev Bras Hematol Hemoter. 2010;32(1):56-62. http://dx.doi.org/10.1590/S1516-84842010005000001

5. Pinto PCA, Braga JAP, Santos AMN. Fatores de risco para aloimunização em pacientes com anemia falciforme. Rev Assoc Méd Bras. 2011;57(6):668-73. http://dx.doi.org/10.1590/S0104-42302011000600014

6. Cançado RD, Jesus JA. A doença falciforme no Brasil. Rev Bras Hematol Hemoter. 2007;29(3):203-6. http://dx.doi.org/10.1590/S1516-84842007000300002

7. Helman R, Cançado RD, Olivatto C. Incidência de aloimunização eritrocitária em pacientes com doença falciforme: experiência de um centro em São Paulo. Einstein. 2011;9(2):160-4. http://dx.doi.org/10.1590/S1679-45082011AO2003

8. Moreira GA. Repercussões respiratórias da anemia falciforme. J Bras Pneumol. 2007;33(3):18-20. http://dx.doi.org/10.1590/S1806-37132007000300002

9. Figueiredo AKB, Santos FAV, Soares LH, Sousa NDL. Anemia falciforme: abordagem diagnóstica laboratorial. Rev Ciênc Saúde Nova Esperança. 2014;12(1):96-103.

10. Lobo CLC, Bueno LM, Moura P, Ogeda LL, Castilho S, Carvalho SMF. Triagem neonatal para hemoglobinopatias no Rio de Janeiro, Brasil. Rev Panam Salud Publica. 2003;13(2-3):154-9. http://dx.doi.org/10.1590/S1020-49892003000200018

11. Brasil. Ministério da Saúde. Secretaria de Assistência à Saúde. Coordenação Geral de Atenção Especializada. Manual de Normas Técnicas e Rotinas Operacionais do Programa Nacional de Triagem Neonatal. Brasília: Ministério da Saúde; 2002.

12. Chou ST. Transfusion therapy for sickle cell disease: a balacing act. Hematology Am Soc Hematol Educ Program. 2013;2013(1):439-46. http://dx.doi.org/10.1182/asheducation-2013.1.439

13. Natukunda B, Schonewille H, Ndugwa C, Brand A. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion. 2010;50(1):20-5. http://dx.doi.org/10.1111/j.1537-2995.2009.02435.x

14. Rodrigues R, Gerônimo DS, Mella Junior SE, Peron MLDF. Aplicabilidade da fenotipagem eritrocitária em doadores voluntários e pacientes politransfundidos. Saúde Pesquisa. 2013;6(3):387-97. http://dx.doi.org/10.17765/1983-1870.2013v6n3p%25p

15. Campbell-Lee SA, Kittles RA. Red blood cell alloimunization in sickle cell: listen to your ancestors. Transfus Med Hemother. 2014;41(6):431-5. http://dx.doi.org/10.1159/000369513

16. Karafin MS, Denomme GA, Bryant BJ. The future of red blood cell alloimmunization risk reduction. Transfusion. 2015;55(1):220-21. http://dx.doi.org/10.1111/trf.12863

17. Godfrey GJ, Lockwood W, Kong M, Bertolone S, Ray A. Antibody development in pediatyric cell patients undergoing erythocytapheresis. Pediatr Blood Cancer. 2010;55(6):1134-37. http://dx.doi.org/10.1002/pbc.22647

18. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3):528-37. http://dx.doi.org/10.1182/blood-2011-11-327361

19. Alves VM, Martins PRJ, Soares S, Araújo G, Schmidt LC, Costa SSM, et al. Alloimmunization screening after transfusion of red blood cells in a prospective study. Rev Bras Hematol Hemoter. 2012;34(3):206-11. http://dx.doi.org/10.5581/1516-8484.20120051

20. Kangiwa U, Ibegbulam O, Ocheni S, Madu A, Mohammed N. Pattern and prevalence of alloimmunization in multiply transfused patients with sickle cell disease in Nigeria. Biomarker Res. 2015;3(26):1-6. http://dx.doi.org/10.1186/s40364-015-0050-3

21. Noizat-pirenne F. Relevance of blood groups in transfusion of sickle cell disease patients. C R Biol. 2013;336(3):152-8. http://dx.doi.org/10.1016/j.crvi.2012.09.011

22. Oliveira LCO, Cozac APCNC. Reações transfusionais: diagnóstico e tratamento. Medicina. 2003;36(2/4):431-38. http://dx.doi.org/10.11606/issn.2176-7262.v36i2/4p431-438.

23. Schonewille H, van de Watering LM, Loomans DS, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion. 2006;46(2):250-6. http://dx.doi.org/10.1111/j.1537-2995.2006.00708.x

24. Gomes GG. Avaliação de aloimunização e autoimunização eritrocitária em crianças portadoras de anemia falciforme, indicadas ao regime de hipertransfusão por dopller transcraniano alterado ou acidente vascular encefálico instalado. Monografia (Graduação em Medicina) – Faculdade de Medicina da Universidade Federal da Bahia, Salvador; 2014.

25. Yazdanbakhsh K. Mechanisms of sickle cell alloimmunization. Transfus Clin Biol. 2015;22(3):178-81. http://dx.doi.org/10.1016/j.tracli.2015.05.005

26. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23):1617-21. http://dx.doi.org/10.1056/NEJM199006073222301

27. Murao M, Viana MB. Risk factors for alloimmunization by patients with sickle cell disease. Braz J Med Biol Res. 2005;38(5):675-82. http://dx.doi.org/10.1590/S0100-879X2005000500004

28. Natukunda B, Schonewille H, Van de Watering L, Brand A. Prevalence and specificities of red blood cell alloantibodies in transfused Ugandans with different diseases. Vox Sang. 2010;98(2):167-71. http://dx.doi.org/10.1111/j.1423-0410.2009.01241.x

29. Ugwu NI, Awodu OA, Bazuaye GN, Okoye. Red cell alloimmunization in multi-transfused patients with sickle cell anemia in Benin City, Nigeria. Nijer J Clin Pract. 2015;18(4):522-6. http://dx.doi.org/10.4103/1119-3077.154204

30. Elenga N, Niel L. Alloimmunization in patients with sickle cell disease in French Guiana. J Blood Transfu. 2015;2015:3. http://dx.doi.org/10.1155/2015/812934

31. Chou ST, Jackson T, Vege S, Smith-Whitjey K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6):1062-71. http://dx.doi.org/10.1182/blood-2013-03-490623

32. Martins PRJ, Alves VM, Pereira GA, Souza HM. Frequência de anticorpos irregulares em politransfundidos no Hemocentro Regional de Uberaba-MG, de 1997 a 2005. Rev Bras Hematol Hemoter. 2008;30(4):272-76. http://dx.doi.org/10.1590/S1516-84842008000400008

33. Jens E, Pagliarini T, Novaretti MCZ. Sistema de grupo sanguíneo Duffy: biologia e prática transfusional. Rev Bras Hematol Hemoter. 2005;27(2):110-19. http://dx.doi.org/10.1590/S1516-84842005000200011

34. Lasalle-Williams M, Nuss R, Le T, Cole L, Hassel K, Murphy Jr, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion. 2011;51(8):1732-39. http://dx.doi.org/10.1111/j.1537-2995.2010.03045.x

35. Ryder AB, Zimring JC, Hendrickson JE. Factors Influencing RBC alloimmunization: lessons learned from murine models. Transfus Med Hemother. 2014;41(6):406-19. http://dx.doi.org/10.1159/000368995

36. Castilho L, Rios M, Bianco C, Pelegrino J, Alberto FL, Saad ST, et al. DNA-based typing of blood groups for the management of multiply-transfused sickle cell disease patients. Transfusion. 2002;42(2):232-8. http://dx.doi.org/10.1046/j.1537-2995.2002.00029.x

37. Anstee DJ. Red cell genotyping and the future of pretransfusion testing. Blood. 2009;114(2):248-56. http://dx.doi.org/10.1182/blood-2008-11-146860